Enanta Pharma (ENTA) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Join SI Premium – FREE
Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.85), $0.01 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $18.31 million versus the consensus estimate of $16.17 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
- Cboe launches binary options suite tied to Mini-S&P 500 Index
- Obsidian Energy Increases Syndicated Credit Facility
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
